ZTEK (Zentek) Institutional Ownership : 1.64% (As of Mar. 29, 2025)

View and export this data going back to 2012. Start your Free Trial

What is Zentek Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Zentek's institutional ownership is 1.64%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Zentek's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Zentek's Float Percentage Of Total Shares Outstanding is 94.84%.

Zentek Institutional Ownership Historical Data

The historical data trend for Zentek's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zentek Institutional Ownership Chart

Zentek Historical Data

The historical data trend for Zentek can be seen below:

	2021-01-31	2021-02-28	2021-03-31	2021-04-30	2021-05-31	2021-06-30	2021-07-31	2021-08-31	2021-09-30	2021-10-31
Institutional Ownership	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03

Zentek Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Zentek Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zentek Ltd (NAS:ZTEK) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

ZAY:Germany ZEN:Canada

Address

24 Corporate Court, Guelph, ON, CAN, N1G 5G5

Website

https://www.zentek.com

Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.